Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 _____ ...

OraSure Technologies (OSUR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.67%. A quarter ago, it was expected that this diagnostic test maker would post a loss of $0.15 per share when it actually produced a loss of $0.18, delivering a surprise of -20%.Over the last four quarters, th ...

Financial Data and Key Metrics Changes - Total revenue in Q2 was $31.2 million, with core revenue at $30.8 million, which was above the midpoint of guidance [21] - Core revenue growth would have been positive year over year if excluding the decline from a large consumer genetics customer [21] - GAAP gross margin was 42.1%, and non-GAAP gross margin was 43.2%, better than expectations [22] - GAAP operating loss in Q2 was $18 million, while non-GAAP operating loss was $13.2 million [23] - Operating cash flow in Q2 was negative $10 million, consistent with expectations due to investments in innovation [23] Business Line Data and Key Metrics Changes - Diagnostics revenue was $19.2 million in Q2, growing 3% year over year [21] - Sample Management Solutions revenue was $9.9 million, with growth from other customers excluding the large consumer genetics customer [21] - COVID-19 and risk assessment testing products contributed $474,000 in revenue, consistent with guidance [22] Market Data and Key Metrics Changes - International diagnostics business showed year-over-year revenue growth despite disruptions from USAID funding freezes [8] - US diagnostics revenue declined 1% year over year, with public health customers facing budget cuts and staffing reductions [11] - The "Together Take Me Home" program may continue beyond September 30, with expected revenue of approximately $500,000 in Q3 compared to $2 million in Q2 [12] Company Strategy and Development Direction - The company is focused on three strategic pillars: strengthening the foundation, elevating core growth, and accelerating profitable growth [5] - New product launches, such as HemoCollect protein, aim to meet evolving needs in proteomic research [6][15] - The transition to in-house manufacturing for Sample Management Solutions is expected to improve operational efficiencies starting in 2025 [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in 2026 as customers adapt to the new environment [27] - The company is closely monitoring funding uncertainties in public health programs and research [8][11] - Management highlighted the importance of maintaining strong customer relationships while cultivating new ones [13] Other Important Information - Ann Metzing joined as Chief Commercial Officer to drive sales, marketing, and product management [7] - The company is evaluating inorganic growth opportunities to expand its product portfolio [24] Q&A Session Summary Question: Can you provide specifics on the Q3 guidance regarding HIV and HCV platforms? - Management indicated that Q3 revenue guidance is influenced by the "Together Take Me Home" program and expected slower orders for HIV tests due to inventory management in international markets [33][35] Question: What initial traction has been seen with the HemoCollect protein product? - Management reported enthusiastic customer engagement and highlighted the product's potential in various clinical applications, including oncology and neurology [39][40]

EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch investorinfo@orasure.com media@orasure.com VP, Investor Relations Director, Corporate Communications OraSure Announces Second Quarter 2025 Financial Results BETHLEHEM, PA, August 5, 2025 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. "Our Q2 results were consiste ...

BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closel ...

Core Insights - OraSure Technologies, Inc. has appointed Anne Messing as Chief Commercial Officer, bringing over 25 years of experience in the healthcare industry [1][2] - Ms. Messing will oversee Sales, Marketing, Strategic Alliances, and Product Management, aiming to enhance OTI's market leadership and long-term growth [2][4] - The company focuses on improving healthcare access, quality, and value through innovative diagnostic tests and sample management solutions [5] Company Background - OraSure Technologies is a leader in point-of-need and home diagnostic tests, as well as sample management solutions [1][5] - The company, along with its subsidiaries, develops and distributes rapid diagnostic tests and sample collection devices globally [5] - OTI's products are utilized by various sectors, including clinical laboratories, hospitals, and direct consumers [5] Leadership Experience - Prior to joining OTI, Ms. Messing held a significant role at Becton Dickinson, where she led initiatives that exceeded market benchmarks [3] - Her extensive background includes leadership positions at Danaher, Quest Diagnostics, Siemens Healthcare Diagnostics, and ARUP Laboratories [3] - Ms. Messing has a strong foundation in healthcare, starting her career as a certified medical technologist [3] Strategic Vision - The company aims to leverage Ms. Messing's expertise to drive growth and deliver exceptional value to stakeholders [4] - OTI is preparing for impactful product launches as part of its strategic vision for the future [4]

Core Insights - OraSure Technologies (NASDAQ: OSUR) is currently trading close to its cash value and has virtually no debt, resulting in a very low enterprise value (EV) [1] - The discounted pricing of the company is attributed to market perceptions rather than its fundamental value [1] Investment Philosophy - The company focuses on three main areas: analyzing high-quality growth companies with sustainable competitive advantages, turnaround situations and contrarian investments, and providing insights on broader market conditions and macroeconomic trends [1] - The educational background from the University of Virginia has provided rigorous analytical skills, emphasizing disciplined research and long-term perspectives [1] Market Position - The company is positioned to uncover emerging growth stories before they gain widespread attention, indicating a proactive investment strategy [1] - There is a commitment to sharing well-researched investment ideas and market insights to assist investors in making informed decisions [1]

Core Points - OraSure Technologies, Inc. has scheduled its earnings conference call for second quarter 2025 financial results on August 5, 2025, at 5 p.m. ET [1] - A webcast of the conference call will be available on OraSure's investor relations page and will be archived for approximately one year [2] - Participants interested in asking questions during the call must pre-register to receive access details via email [3] Company Overview - OraSure Technologies, Inc. focuses on transforming health through actionable insights and improving access, quality, and value of healthcare with innovative testing and sample management solutions [3] - The company, along with its subsidiaries, is a leader in developing, manufacturing, and distributing rapid diagnostic tests and sample collection devices for critical medical conditions [3] - OraSure's products are sold globally to various sectors including clinical laboratories, hospitals, and direct consumers [3]

Core Insights - OraSure Technologies, Inc. has launched the HEMAcollect™ ● PROTEIN product aimed at enhancing proteomic research through improved sample collection and preservation [1][2] - The HEMAcollect™ ● PROTEIN is an evacuated blood collection tube designed to stabilize plasma proteins for up to seven days, addressing limitations of traditional blood collection methods [1][2] - The product is expected to provide operational and financial efficiencies for proteomic researchers, facilitating high-quality data generation [1] Product Features - The HEMAcollect™ ● PROTEIN BCT utilizes ProteoPrecision™ technology to minimize hemolysis and platelet activation, ensuring sample integrity [2] - It is compatible with various proteomic technologies, including mass spectrometry and immunoassays, making it versatile for different research applications [2] Company Overview - OraSure Technologies focuses on transforming healthcare through innovative diagnostic tests and sample management solutions, serving a wide range of customers including clinical laboratories and pharmaceutical companies [4] - DNA Genotek, a subsidiary of OraSure, specializes in developing products that optimize sample collection and performance for high-quality biological samples [5]

Investment Rationale & Financial Strength - The company is an industry leader in rapid point-of-care infectious disease testing and DNA/RNA sample self-collection, stabilization, and preparation products[5] - The company has a strong balance sheet with over $178 million in cash and investments, no debt, and sustainable profitability[5, 63] Molecular Solutions Growth - Molecular solutions are experiencing growth from existing customers and increased demand from emerging genetic testing offerings and large studies[19] - In November 2017, the company announced a $143 million supply agreement for OrageneDx to a leading consumer genomics customer, over several years, with minimum annual purchase requirements[24] - The company's products drive scalability and access to donors in human genome testing[27] Infectious Disease Solutions & Market Opportunities - Approximately 36.7 million people are living with HIV, and there were 1.8 million new infections in 2016[46] - An estimated 71 million people globally have chronic hepatitis C infection, with approximately 399,000 deaths each year from HCV[56] - The company was awarded a $10.4 million BARDA contract for Ebola and $16.6 million BARDA contract for Zika[60, 61]